Humacyte's vascular graft revenue edges past $1m as company eyes dialysis label expansion

Humacyte is beginning to show a commercial trajectory for Symvess, its engineered vessel for repairing vascular injuries. The company said on 10 November that third-quarter sales reached $1.0m, against $0.4m in the second quarter, and that 49 hospitals have now placed orders.

The numbers remain small, and the facts available do not include Humacyte's wider financial results, so the revenue figure cannot be set against costs, cash or guidance. What the data do show is a product moving from first orders towards broader hospital adoption.

The next commercial lever is a label expansion. Humacyte intends to file a supplemental Biologics License Application with the US Food and Drug Administration in November 2026, seeking to add dialysis access to the approved uses of its acellular tissue engineered vessel. By way of context, an sBLA is the mechanism a sponsor uses to ask the agency to approve a new indication for an already licensed biologic. The company has not been reported here as having submitted the filing yet, and details of its contents were not provided.

Separately, Humacyte has started a Phase 2a first-in-human study of its coronary tissue engineered vessel in coronary artery bypass grafting. The trial followed the FDA's acceptance of the company's Investigational New Drug application. Design details of the study were not disclosed in the information available.